Artivion, Inc. (AORT) SEC Filings & Earnings Calls

Acquisition Integration Risk

“$11.7 million of Endospan acquisition transaction costs, of which $10.2 million related to transaction bonuses for Endospan employees associated with the Endospan acquisition” · word for word

Single-Source Supplier Dependency

“We are dependent on single and sole-source suppliers and single facilities.” · word for word

Regulatory Risk (MDR, FDA reclassification)

“The European Union’s Medical Device Regulation (the MDR), which was to be fully implemented on May 26, 2021, places stricter requirements on manufacturers ... could result in product reclassifications or the imposition of other regulatory requirements” · word for word

Net loss on GAAP basis due to acquisition-related costs and amortization

“Net loss for the second quarter of 2026 was $(13.5) million” · word for word

Integration risk from Endospan acquisition and associated $8M expense in 2026

“expect to incur approximately $8 million of expense through the full year 2026 associated with the acquisition of Endospan”

Foreign currency revaluation losses of $0.7M in non-GAAP net income

“Non-GAAP net income for the second quarter of 2026 includes pretax losses related to foreign currency revaluation of $0.7 million” · word for word

Integration risk: successful integration of Endospan's operations and technology is uncertain

“risks related to Artivion’s ability to successfully integrate Endospan’s operations and technology” · word for word

Contingent consideration liability: up to $200M payable based on NEXUS performance, could impact future cash flows

“contingent consideration of up to $200.0 million based on the future performance of Endospan’s Nexus™ product” · word for word

Single-source supplier dependency

“Some of the materials, supplies, and services used in our product manufacturing and tissue processing, as well as some of our products, are sourced from single- or sole-source suppliers.” · word for word

Cybersecurity incident recurrence

“We experienced a previously-disclosed cybersecurity incident in the fourth quarter of 2024 that temporarily disrupted our business operations, including our ERP systems, and had an impact on revenue, manufacturing, order processing, shipping, and other corporate operations.” · word for word

Regulatory reclassification of CryoValve SGPV

“If the FDA ultimately classifies our CryoValve SGPV as a Class III medical device, and if there are delays in obtaining the PMA, if we are unsuccessful in obtaining the PMA, or if the costs associated with these activities are significant, we could decide that the requirements for continued processing of the CryoValve SGPV are too onerous, leading us to disc” · word for word

MDR transition delays

“The transition to the MDR has been fraught with difficulties and uncertainty, including delays in audits and approvals.” · word for word

Debt-funded acquisition increases financial leverage and interest expense.

“Artivion intends to fund the purchase price through borrowings under its previously disclosed term loan facility.”

Contingent consideration based on future product performance introduces uncertainty.

“contingent consideration of up to $200.0 million based on the future performance of Endospan’s Nexus product”

Italian government payback reserve of $2.3M reduces reported revenue.

“Adjusted revenue excludes $2.3 million reserve for estimated payback to Italian government.”

Cybersecurity Incident Residual Impact

“We continue to incur expenses in connection with improving our global infrastructure and cybersecurity posture. Additionally, we remain subject to other risks and uncertainties as a result of the incident, including those related to scrap, inventory levels, and timely shipping releases, as well as the potential to incur additional expenses.” · word for word

Single-Source Supplier Dependency

“We are dependent on single and sole-source suppliers and single facilities. Some of the materials, supplies, and services used in our product manufacturing and tissue processing, as well as some of our products, are sourced from single- or sole-source suppliers.” · word for word

Regulatory Risk - MDR Transition

“The European Union’s Medical Device Regulation (the MDR), which was to be fully implemented on May 26, 2021, places stricter requirements on manufacturers and European Notified Bodies regarding, among other things, product classifications and pre- and post-market clinical studies for product clearances and approvals.” · word for word

EtO Sterilization Regulatory Risk

“Concerns about the release of EtO into the environment at unsafe levels have led to increased activism and lobbying as well as various regulatory enforcement activities against EtO facilities, including closures and temporary closures, lawsuits against EtO service providers, and proposals increasing regulations related to EtO.” · word for word

Foreign currency revaluation losses of $0.1M pretax; slight negative impact.

“pretax losses related to foreign currency revaluation of $0.1 million” · word for word